- Home
- Publications
- Publication Search
- Publication Details
Title
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 11, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-08-28
DOI
10.3389/fimmu.2020.01986
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Ramucirumab: A Review in Hepatocellular Carcinoma
- (2020) Yahiya Y. Syed DRUGS
- Atezolizumab for the treatment of breast cancer
- (2020) Sangeetha M. Reddy et al. Expert Review of Anticancer Therapy
- Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study
- (2020) Elliott Geoffrey Playford et al. LANCET INFECTIOUS DISEASES
- Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
- (2020) Steven G. Gray et al. Translational Lung Cancer Research
- Vaccination Strategies and Immune Modulation of Atherosclerosis
- (2020) Jan Nilsson et al. CIRCULATION RESEARCH
- Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial
- (2020) Atul Deodhar et al. LANCET
- Developing therapeutic monoclonal antibodies at pandemic pace
- (2020) Brian Kelley NATURE BIOTECHNOLOGY
- IL-23 inhibitor guselkumab shows promise for PsA
- (2020) Jessica McHugh Nature Reviews Rheumatology
- COVID-19 and Cancer: a Comprehensive Review
- (2020) Rohit Gosain et al. Current Oncology Reports
- Machine Learning-Guided Prediction of Antigen-Reactive In Silico Clonotypes Based on Changes in Clonal Abundance through Bio-Panning
- (2020) Duck Kyun Yoo et al. Biomolecules
- Laboratory monitoring of hemophilia A treatments: new challenges
- (2020) Peter J. Lenting Blood Advances
- Safety and Tolerability of Antibody-Drug Conjugates in Cancer
- (2019) Anna Wolska-Washer et al. DRUG SAFETY
- Emapalumab: First Global Approval
- (2019) Zaina T. Al-Salama DRUGS
- Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Andrew X Zhu et al. LANCET ONCOLOGY
- ALTHEA Gold Libraries™: Antibody libraries for therapeutic antibody discovery
- (2019) Philippe Valadon et al. mAbs
- Efficacy and Safety of Belimumab and Azathioprine for Maintenance of Remission in ANCA-Associated Vasculitis: A Randomized Controlled Study
- (2019) David Jayne et al. Arthritis & Rheumatology
- Phage display derived therapeutic antibodies have enriched aliphatic content: Insights for developability issues
- (2019) Nazlı Eda Kaleli et al. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
- Five computational developability guidelines for therapeutic antibody profiling
- (2019) Matthew I. J. Raybould et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Top drugs and companies by sales in 2018
- (2019) Lisa Urquhart NATURE REVIEWS DRUG DISCOVERY
- Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study
- (2019) Alice Bitossi et al. MEDIATORS OF INFLAMMATION
- High-throughput retrieval of physical DNA for NGS-identifiable clones in phage display library
- (2019) Jinsung Noh et al. mAbs
- Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity
- (2019) Thomas Dörner et al. ANNALS OF THE RHEUMATIC DISEASES
- Adalimumab Medium‐Term Dosing Strategy in Moderate‐to‐Severe Hidradenitis Suppurativa: Integrated Results from the Phase 3, Randomized, Placebo‐Controlled, PIONEER Trials
- (2019) G.B.E. Jemec et al. BRITISH JOURNAL OF DERMATOLOGY
- Moxetumomab pasudotox-tdfk for relapsed/refractory hairy cell leukemia: a review of clinical considerations
- (2019) Carmen F. Nobre et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Action on neovascular age-related macular degeneration (nAMD): recommendations for management and service provision in the UK hospital eye service
- (2019) Richard P. Gale et al. EYE
- Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential Molecules
- (2019) Marcella Nebbioso et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement.
- (2019) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- A comprehensive search of functional sequence space using large mammalian display libraries created by gene editing
- (2019) Kothai Parthiban et al. mAbs
- Non-Hodgkin lymphoma therapy landscape
- (2019) Kritika Chaudhari et al. NATURE REVIEWS DRUG DISCOVERY
- Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild‐Type Non‐Small Cell Lung Cancer
- (2019) Lecia V. Sequist et al. ONCOLOGIST
- Plant/Bacterial Virus-Based Drug Discovery, Drug Delivery, and Therapeutics
- (2019) Sokullu et al. Pharmaceutics
- Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial
- (2019) Diego Cadavid et al. LANCET NEUROLOGY
- A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer
- (2019) Zishuo Ian Hu et al. Cancer Medicine
- Current Clinical Trials in Pemphigus and Pemphigoid
- (2019) Kentaro Izumi et al. Frontiers in Immunology
- Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis
- (2019) Mounica Vallurupalli et al. BLOOD
- Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects
- (2019) Chiara Crotti et al. DRUGS
- Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer
- (2019) Uqba Khan et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Phage display antibody libraries: A robust approach for generation of recombinant human monoclonal antibodies
- (2019) Rajesh Kumar et al. INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
- Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial
- (2019) Michael G Hanna et al. LANCET NEUROLOGY
- Belimumab alters transitional B-cell subset proportions in patients with stable systemic lupus erythematosus
- (2019) A Benitez et al. LUPUS
- Sequence features of variable region determining physicochemical properties and polyreactivity of therapeutic antibodies
- (2019) Maxime Lecerf et al. MOLECULAR IMMUNOLOGY
- Antibody-cytokine fusion proteins: A novel class of biopharmaceuticals for the therapy of cancer and of chronic inflammation
- (2019) Patrizia Murer et al. New Biotechnology
- Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)
- (2019) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- Contextualizing the Use of Moxetumomab Pasudotox in the Treatment of Relapsed or Refractory Hairy Cell Leukemia
- (2019) Robert J. Kreitman et al. ONCOLOGIST
- Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI
- (2019) Martina Schaefer et al. JOURNAL OF MOLECULAR BIOLOGY
- Antibodies to watch in 2020
- (2019) Hélène Kaplon et al. mAbs
- Biologics in Chronic Rhinosinusitis: An Update and Thoughts for Future Directions
- (2018) Kristine A. Smith et al. American Journal of Rhinology & Allergy
- Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
- (2018) Silvia C. Formenti et al. CLINICAL CANCER RESEARCH
- RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma
- (2018) Martina Imbimbo et al. Clinical Lung Cancer
- Biologics for the primary care physician: Review and treatment of psoriasis
- (2018) Eric D. Schadler et al. DM DISEASE-A-MONTH
- Belimumab: A Review in Systemic Lupus Erythematosus
- (2018) Hannah A. Blair et al. DRUGS
- Avelumab (anti-PD-L1) in platinum-resistant/refractory ovarian cancer: JAVELIN Ovarian 200 Phase III study design
- (2018) Eric Pujade-Lauraine et al. Future Oncology
- Toll-like receptor 3 blockade in rhinovirus-induced experimental asthma exacerbations: A randomized controlled study
- (2018) Philip E. Silkoff et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
- (2018) Andreas Wollenberg et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Factor XIa Inhibitors as New Anticoagulants
- (2018) Mimi L. Quan et al. JOURNAL OF MEDICINAL CHEMISTRY
- Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Atul Deodhar et al. LANCET
- Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia
- (2018) Robert J. Kreitman et al. LEUKEMIA
- Healthcare utilisation prior to the diagnosis of inflammatory bowel diseases and the influence of livestock exposure: A longitudinal case-control study
- (2018) Baukje J. van der Star et al. PLoS One
- Identification of high affinity HER2 binding antibodies using CHO Fab surface display
- (2018) Annalee W Nguyen et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Avelumab: A Review in Metastatic Merkel Cell Carcinoma
- (2018) Matt Shirley Targeted Oncology
- The Increasingly Human and Profitable Monoclonal Antibody Market
- (2018) António L. Grilo et al. TRENDS IN BIOTECHNOLOGY
- Basics of Antibody Phage Display Technology
- (2018) Line Ledsgaard et al. Toxins
- Efficacy and Safety of Guselkumab, an Anti–interleukin 23 Monoclonal Antibody, for Palmoplantar Pustulosis
- (2018) Tadashi Terui et al. JAMA Dermatology
- Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials
- (2018) Reynold A Panettieri et al. Lancet Respiratory Medicine
- Progress and Challenges in the Design and Clinical Development of Antibodies for Cancer Therapy
- (2018) Juan C. Almagro et al. Frontiers in Immunology
- Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab
- (2018) Andrew D. Cook et al. Therapeutic Advances in Musculoskeletal Disease
- Phase III, randomised trial of avelumab versus physician’s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300
- (2018) Y -J Bang et al. ANNALS OF ONCOLOGY
- GM-CSF as a therapeutic target in psoriasis: randomised, controlled investigation using namilumab - a specific, human anti-GM-CSF monoclonal antibody
- (2018) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis
- (2018) Andrew Blauvelt et al. CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
- Lanadelumab: First Global Approval
- (2018) Yahiya Y. Syed DRUGS
- Real-world data on ranibizumab for myopic choroidal neovascularization due to pathologic myopia: results from a post-marketing surveillance in Japan
- (2018) Kyoko Ohno-Matsui et al. EYE
- Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β
- (2018) Bernd Bohrmann et al. JOURNAL OF ALZHEIMERS DISEASE
- Safety, efficacy and pharmacodynamics (PD) of MEDI9447 (oleclumab) alone or in combination with durvalumab in advanced colorectal cancer (CRC) or pancreatic cancer (panc).
- (2018) Michael J. Overman et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma
- (2018) Rimas V. Lukas et al. JOURNAL OF NEURO-ONCOLOGY
- Long-term safety profile of ixekizumab in patients with moderate-to-severe plaque psoriasis: An integrated analysis from 11 clinical trials
- (2018) R G Langley et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study
- (2018) Fabrice Barlesi et al. LANCET ONCOLOGY
- Structural diversity and flexibility of diabodies
- (2018) Na-Young Kwon et al. METHODS
- Safety of Ixekizumab in Patients with Psoriatic Arthritis: Results from a Pooled Analysis of Three Clinical Trials
- (2018) Philip Mease et al. ARTHRITIS CARE & RESEARCH
- Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models
- (2018) Maria Quanz et al. Oncotarget
- Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma
- (2018) Jun Zhang et al. Frontiers in Oncology
- Safety and pharmacokinetics of MM-302, a HER2-targeted antibody–liposomal doxorubicin conjugate, in patients with advanced HER2-positive breast cancer: a phase 1 dose-escalation study
- (2018) Pamela Munster et al. BRITISH JOURNAL OF CANCER
- Caplacizumab: First Global Approval
- (2018) Sean Duggan DRUGS
- Necitumumab for the treatment of advanced non-small-cell lung cancer
- (2018) Asunción Díaz-Serrano et al. Future Oncology
- A phase 1 dose escalation and expansion study of Tarextumab (OMP-59R5) in patients with solid tumors
- (2018) David C. Smith et al. INVESTIGATIONAL NEW DRUGS
- Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks
- (2018) Aleena Banerji et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Long-term efficacy and safety of ixekizumab in Japanese patients with erythrodermic or generalized pustular psoriasis: subgroup analyses of an open-label, phase 3 study (UNCOVER-J)
- (2018) Y. Okubo et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Antibodies to watch in 2019
- (2018) Hélène Kaplon et al. mAbs
- In vitro and in silico assessment of the developability of a designed monoclonal antibody library
- (2018) Adriana-Michelle Wolf Pérez et al. mAbs
- Cancer immunologists scoop medicine Nobel prize
- (2018) Heidi Ledford et al. NATURE
- Biopharmaceutical benchmarks 2018
- (2018) Gary Walsh NATURE BIOTECHNOLOGY
- Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: 16 Week Results of a Phase 3 Randomized, Double-Blind, Placebo Controlled Trial in Patients with Prior Inadequate Response or Intolerance to Tumor Necrosis Factor
- (2018) Atul Deodhar et al. Arthritis & Rheumatology
- Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial
- (2018) Christophe Le Tourneau et al. Journal for ImmunoTherapy of Cancer
- High-concentration protein formulations: How high is high?
- (2017) Patrick Garidel et al. EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
- The role of IL 23 in the treatment of psoriasis
- (2017) Lluís Puig Expert Review of Clinical Immunology
- Pathogenesis of Hereditary Angioedema
- (2017) Allen P. Kaplan et al. IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA
- Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors
- (2017) Su Jin Lee et al. INVESTIGATIONAL NEW DRUGS
- BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial
- (2017) Francis H Glorieux et al. JOURNAL OF BONE AND MINERAL RESEARCH
- Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia
- (2017) Lothar Seefried et al. JOURNAL OF CLINICAL INVESTIGATION
- Results of a randomized phase II trial of an anti-notch 2/3, tarextumab (OMP-59R5, TRXT, anti-Notch2/3), in combination with nab-paclitaxel and gemcitabine (Nab-P+Gem) in patients (pts) with untreated metastatic pancreatic cancer (mPC).
- (2017) Eileen Mary O'Reilly et al. JOURNAL OF CLINICAL ONCOLOGY
- CNTO6785, a Fully Human Antiinterleukin 17 Monoclonal Antibody, in Patients with Rheumatoid Arthritis with Inadequate Response to Methotrexate: A Randomized, Placebo-controlled, Phase II, Dose-ranging Study
- (2017) Philip J. Mease et al. JOURNAL OF RHEUMATOLOGY
- Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study
- (2017) Daniel Rooks et al. JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
- P3.02b-005 Phase Ib Trial of Afatinib and BI 836845 in Advanced NSCLC: Dose Escalation and Safety Results
- (2017) Keunchil Park et al. Journal of Thoracic Oncology
- Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
- (2017) Daniel P Petrylak et al. LANCET
- Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trial
- (2017) Diego Cadavid et al. LANCET NEUROLOGY
- Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
- (2017) Christopher R Heery et al. LANCET ONCOLOGY
- Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial
- (2017) James L Gulley et al. LANCET ONCOLOGY
- Preclinical Antitumor Efficacy of BAY 1129980—a Novel Auristatin-Based Anti-C4.4A (LYPD3) Antibody–Drug Conjugate for the Treatment of Non–Small Cell Lung Cancer
- (2017) Jörg Willuda et al. MOLECULAR CANCER THERAPEUTICS
- Next generation antibody drugs: pursuit of the 'high-hanging fruit'
- (2017) Paul J. Carter et al. NATURE REVIEWS DRUG DISCOVERY
- The renaissance of complement therapeutics
- (2017) Daniel Ricklin et al. Nature Reviews Nephrology
- Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis
- (2017) Aleena Banerji et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biophysical properties of the clinical-stage antibody landscape
- (2017) Tushar Jain et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies
- (2017) Aaron Simpson et al. Targeted Oncology
- Amatuximab and novel agents targeting mesothelin for solid tumors
- (2017) Paolo Baldo et al. OncoTargets and Therapy
- Remembering Emil von Behring: from Tetanus Treatment to Antibody Cooperation with Phagocytes
- (2017) Stefan H. E. Kaufmann mBio
- Effect of DNA sequence of Fab fragment on yield characteristics and cell growth of E. coli
- (2017) Antti Kulmala et al. Scientific Reports
- A phase III randomized trial of gantenerumab in prodromal Alzheimer’s disease
- (2017) Susanne Ostrowitzki et al. Alzheimers Research & Therapy
- Product review on the Anti-PD-L1 antibody atezolizumab
- (2017) Neil J. Shah et al. Human Vaccines & Immunotherapeutics
- Antibody Engineering for Pursuing a Healthier Future
- (2017) Abdullah F. U. H. Saeed et al. Frontiers in Microbiology
- Effect of bimagrumab on thigh muscle volume and composition in men with casting-induced atrophy
- (2017) Daniel S. Rooks et al. Journal of Cachexia Sarcopenia and Muscle
- A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis
- (2017) Michael E. Weinblatt et al. Arthritis & Rheumatology
- Atezolizumab for the treatment of non-small cell lung cancer
- (2017) Fernando C. Santini et al. Expert Review of Clinical Pharmacology
- PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
- (2017) Hashem O. Alsaab et al. Frontiers in Pharmacology
- Thrombotic thrombocytopenic purpura
- (2017) Johanna A. Kremer Hovinga et al. Nature Reviews Disease Primers
- WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death
- (2017) Marcus M. Fischer et al. Science Advances
- Adalimumab in the Treatment of Immune-Mediated Diseases
- (2017) G. Lapadula et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- Phase II study of PRO95780 plus rituximab in patients with relapsed follicular non-Hodgkin's lymphoma (NHL).
- (2017) S. Wittebol et al. JOURNAL OF CLINICAL ONCOLOGY
- A single-arm, open-label, phase 2 clinical trial evaluating disease response following treatment with BI-505, a human anti-intercellular adhesion molecule-1 monoclonal antibody, in patients with smoldering multiple myeloma
- (2017) Stina Wichert et al. PLoS One
- Rapid and accurate in silico solubility screening of a monoclonal antibody library
- (2017) Pietro Sormanni et al. Scientific Reports
- Pharmacokinetics, Pharmacodynamics, and Safety of MEDI4212, an Anti-IgE Monoclonal Antibody, in Subjects with Atopy: A Phase I Study
- (2016) Eric Sheldon et al. ADVANCES IN THERAPY
- PD-011Safety and efficacy analysis of imalumab, an anti-oxidized macrophage migration inhibitory factor (oxMIF) antibody, alone or in combination with 5-fluorouracil/leucovorin (5-FU/LV) or panitumumab, in patients with metastatic colorectal cancer (mCRC)
- (2016) D. Mahalingam et al. ANNALS OF ONCOLOGY
- Assessing the Immunogenicity of Biopharmaceuticals
- (2016) Carlos Pineda et al. BIODRUGS
- Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis
- (2016) R. Das et al. BLOOD
- HERMIONE: a randomized Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice plus trastuzumab in patients with previously treated, anthracycline-naïve, HER2-positive, locally advanced/metastatic breast cancer
- (2016) Kathy Miller et al. BMC CANCER
- Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer
- (2016) E Elez et al. BRITISH JOURNAL OF CANCER
- 2016 US lymphoid malignancy statistics by World Health Organization subtypes
- (2016) Lauren R. Teras et al. CA-A CANCER JOURNAL FOR CLINICIANS
- LJM716 in Japanese patients with head and neck squamous cell carcinoma or HER2-overexpressing breast or gastric cancer
- (2016) Shunji Takahashi et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Phase 1 study of the anti-vascular endothelial growth factor receptor 3 monoclonal antibody LY3022856/IMC-3C5 in patients with advanced and refractory solid tumors and advanced colorectal cancer
- (2016) Muhammad Wasif Saif et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Preclinical Efficacy of the Auristatin-Based Antibody–Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors
- (2016) Anette Sommer et al. CANCER RESEARCH
- A Phase I, First-in-Human Study of AMG 780, an Angiopoietin-1 and -2 Inhibitor, in Patients with Advanced Solid Tumors
- (2016) A. Dowlati et al. CLINICAL CANCER RESEARCH
- Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer
- (2016) Brant A. Inman et al. CLINICAL CANCER RESEARCH
- Merkel Cell Carcinoma Therapeutic Update
- (2016) Nicole M. Cassler et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Novel therapeutic options for cachexia and sarcopenia
- (2016) Alessio Molfino et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
- (2016) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Anti-PEG antibodies in the clinic: Current issues and beyond PEGylation
- (2016) Peng Zhang et al. JOURNAL OF CONTROLLED RELEASE
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
- (2016) Howard L Kaufman et al. LANCET ONCOLOGY
- Phage display-derived human antibodies in clinical development and therapy
- (2016) André Frenzel et al. mAbs
- Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds
- (2016) Magdalena Malm et al. mAbs
- A comprehensive map of molecular drug targets
- (2016) Rita Santos et al. NATURE REVIEWS DRUG DISCOVERY
- Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
- (2016) Flora Peyvandi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The diversity of H3 loops determines the antigen-binding tendencies of antibody CDR loops
- (2016) Yuko Tsuchiya et al. PROTEIN SCIENCE
- Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
- (2016) H. Rexer et al. UROLOGE
- Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
- (2016) H. Rexer et al. UROLOGE
- Targeting membrane proteins for antibody discovery using phage display
- (2016) Martina L. Jones et al. Scientific Reports
- Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy
- (2016) Helena Verdaguer et al. Therapeutic Advances in Medical Oncology
- Novel TGF-β inhibitors ready for prime time in onco-immunology
- (2016) Armand de Gramont et al. OncoImmunology
- Targeting CD73 in the tumor microenvironment with MEDI9447
- (2016) Carl M. Hay et al. OncoImmunology
- Filamentous Bacteriophage: Biology, Phage Display and Nanotechnology Applications
- (2016) CURRENT ISSUES IN MOLECULAR BIOLOGY
- Engineering the surface properties of a human monoclonal antibody prevents self-association and rapid clearance in vivo
- (2016) Claire L. Dobson et al. Scientific Reports
- Phase I study of every 2- or 3-week dosing of ramucirumab, a human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 in patients with advanced solid tumors
- (2015) E. G. Chiorean et al. ANNALS OF ONCOLOGY
- A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial†
- (2015) C. S. Fuchs et al. ANNALS OF ONCOLOGY
- Generation and analysis of the improved human HAL9/10 antibody phage display libraries
- (2015) Jonas Kügler et al. BMC BIOTECHNOLOGY
- Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo
- (2015) Ali Roghanian et al. CANCER CELL
- Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling
- (2015) A. Hultberg et al. CANCER RESEARCH
- FDA Approval Summary: Ramucirumab for Gastric Cancer
- (2015) S. J. Casak et al. CLINICAL CANCER RESEARCH
- Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency
- (2015) W.-C. Yen et al. CLINICAL CANCER RESEARCH
- 16LBA Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC)
- (2015) B. Besse et al. EUROPEAN JOURNAL OF CANCER
- CC-chemokine ligand 2 inhibition in idiopathic pulmonary fibrosis: a phase 2 trial of carlumab
- (2015) Ganesh Raghu et al. EUROPEAN RESPIRATORY JOURNAL
- Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients
- (2015) Lisa M. Rice et al. JOURNAL OF CLINICAL INVESTIGATION
- A New Versatile Immobilization Tag Based on the Ultra High Affinity and Reversibility of the Calmodulin–Calmodulin Binding Peptide Interaction
- (2015) Somnath Mukherjee et al. JOURNAL OF MOLECULAR BIOLOGY
- Developability Assessment During the Selection of Novel Therapeutic Antibodies
- (2015) Alexander Jarasch et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
- (2015) Nick Thatcher et al. LANCET ONCOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- TTAC-0001, a human monoclonal antibody targeting VEGFR-2/KDR, blocks tumor angiogenesis
- (2015) Weon Sup Lee et al. mAbs
- Development and characterization of human monoclonal antibodies that neutralize multiple TGFβ isoforms
- (2015) Daniel Bedinger et al. mAbs
- Boosting antibody developability through rational sequence optimization
- (2015) Daniel Seeliger et al. mAbs
- Camelid Ig V genes reveal significant human homology not seen in therapeutic target genes, providing for a powerful therapeutic antibody platform
- (2015) Alex Klarenbeek et al. mAbs
- Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor-Positive Breast Cancer Model
- (2015) M. D. Curley et al. MOLECULAR CANCER THERAPEUTICS
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- VEGF mRNA and protein concentrations in the developing human eye
- (2015) Irene T. Ma et al. PEDIATRIC RESEARCH
- FDG-PET Imaging for Oxidized LDL in Stable Atherosclerotic Disease: A Phase II Study of Safety, Tolerability, and Anti-Inflammatory Activity
- (2015) Joshua Lehrer-Graiwer et al. JACC-Cardiovascular Imaging
- Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration “Animal Rule”
- (2015) Chia-Wei Tsai et al. Frontiers in Microbiology
- Targeting Interleukin-2 to the Bone Marrow Stroma for Therapy of Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation
- (2015) Christoph Schliemann et al. Cancer Immunology Research
- Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells
- (2015) B. Boyerinas et al. Cancer Immunology Research
- Abstract 4766: Pharmacodynamic and stratification biomarker for the anti-FGFR2 antibody (BAY1179470) and the FGFR2-ADC
- (2015) Christoph A. Schatz et al. CANCER RESEARCH
- Abstract 1022: Development and preclinical testing of AMG 780, a fully human antibody targeting angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2)
- (2015) James V. Bready et al. CANCER RESEARCH
- A phase 1 study investigating DX-2930 in healthy subjects
- (2014) Yung Chyung et al. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY
- Biopharmaceutical liquid formulation: a review of the science of protein stability and solubility in aqueous environments
- (2014) Jordan W. Bye et al. BIOTECHNOLOGY LETTERS
- Abstract S5-04: Primary results of ROSE/TRIO-12, a randomized placebo controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer:
- (2014) JR Mackey et al. CANCER RESEARCH
- High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency
- (2014) C. Suffritti et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma
- (2014) R. Hassan et al. CLINICAL CANCER RESEARCH
- Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non–Small-Cell Lung Cancer
- (2014) Joachim von Pawel et al. Clinical Lung Cancer
- Ramucirumab: First Global Approval
- (2014) Raewyn M. Poole et al. DRUGS
- Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody
- (2014) Jon A. Kenniston et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Four individually druggable MET hotspots mediate HGF-driven tumor progression
- (2014) Cristina Basilico et al. JOURNAL OF CLINICAL INVESTIGATION
- Engineering Antibody Heavy Chain CDR3 to Create a Phage Display Fab Library Rich in Antibodies That Bind Charged Carbohydrates
- (2014) S. Schoonbroodt et al. JOURNAL OF IMMUNOLOGY
- Antibody Phage Display: Technique and Applications
- (2014) Christoph M. Hammers et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- (2014) Edward B Garon et al. LANCET
- A novel IgE-neutralizing antibody for the treatment of severe uncontrolled asthma
- (2014) E Suzanne Cohen et al. mAbs
- Early developability screen of therapeutic antibody candidates using Taylor dispersion analysis and UV area imaging detection
- (2014) Alexandra Lavoisier et al. mAbs
- Effector-Mediated Eradication of Precursor B Acute Lymphoblastic Leukemia with a Novel Fc-Engineered Monoclonal Antibody Targeting the BAFF-R
- (2014) R. Parameswaran et al. MOLECULAR CANCER THERAPEUTICS
- Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
- (2014) S. Golfier et al. MOLECULAR CANCER THERAPEUTICS
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Clinical development success rates for investigational drugs
- (2014) Michael Hay et al. NATURE BIOTECHNOLOGY
- Antibody modeling assessment II. Structures and models
- (2014) Alexey Teplyakov et al. PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS
- Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study
- (2014) Irene Brana et al. Targeted Oncology
- Anthrax lethal and edema toxins in anthrax pathogenesis
- (2014) Shihui Liu et al. TRENDS IN MICROBIOLOGY
- Tailored Immune Responses: Novel Effector Helper T Cell Subsets in Protective Immunity
- (2014) Ervin E. Kara et al. PLoS Pathogens
- A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti-Interleukin-17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors
- (2014) Mark C. Genovese et al. Arthritis & Rheumatology
- Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases
- (2014) Aurelien Amiot et al. Therapeutic Advances in Gastroenterology
- Raxibacumab: potential role in the treatment of inhalational anthrax
- (2014) Carlos Kummerfeldt Infection and Drug Resistance
- Systemic Therapy for Merkel Cell Carcinoma: What’s on the Horizon?
- (2014) Guilherme Rabinowits Cancers
- A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer†
- (2013) A. L. Cohn et al. ANNALS OF ONCOLOGY
- The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity
- (2013) T Hemmerle et al. BRITISH JOURNAL OF CANCER
- A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors
- (2013) Shahneen K. Sandhu et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
- (2013) A. P. Garner et al. CANCER RESEARCH
- A phase II study of cixutumumab (IMC-A12, NSC742460) in advanced hepatocellular carcinoma
- (2013) Ghassan K. Abou-Alfa et al. JOURNAL OF HEPATOLOGY
- Discovery of diverse and functional antibodies from large human repertoire antibody libraries
- (2013) Lauren J. Schwimmer et al. JOURNAL OF IMMUNOLOGICAL METHODS
- ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade
- (2013) Karen Silence et al. mAbs
- A fully synthetic human Fab antibody library based on fixed VH/VL framework pairings with favorable biophysical properties
- (2013) Thomas Tiller et al. mAbs
- Drugs derived from phage display
- (2013) Andrew E Nixon et al. mAbs
- An Antibody Blocking Activin Type II Receptors Induces Strong Skeletal Muscle Hypertrophy and Protects from Atrophy
- (2013) E. Lach-Trifilieff et al. MOLECULAR AND CELLULAR BIOLOGY
- Pharmacodynamic and Antineoplastic Activity of BI 836845, a Fully Human IGF Ligand-Neutralizing Antibody, and Mechanistic Rationale for Combination with Rapamycin
- (2013) K. Friedbichler et al. MOLECULAR CANCER THERAPEUTICS
- High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire
- (2013) Brandon J DeKosky et al. NATURE BIOTECHNOLOGY
- Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: A report from the Children's Oncology Group
- (2013) Brenda Weigel et al. PEDIATRIC BLOOD & CANCER
- Epitope-Specific Mechanisms of IGF1R Inhibition by Ganitumab
- (2013) Frank J. Calzone et al. PLoS One
- A Novel Helper Phage Enabling Construction of Genome-Scale ORF-Enriched Phage Display Libraries
- (2013) Amita Gupta et al. PLoS One
- Tumor Cell Expression of Vascular Endothelial Growth Factor Receptor 2 Is an Adverse Prognostic Factor in Patients with Squamous Cell Carcinoma of the Lung
- (2013) Timothy R. Holzer et al. PLoS One
- The indistinguishability of epitopes from protein surface is explained by the distinct binding preferences of each of the six antigen-binding loops
- (2013) Vered Kunik et al. PROTEIN ENGINEERING DESIGN & SELECTION
- Radretumab Radioimmunotherapy in Patients with Brain Metastasis: A 124I-L19SIP Dosimetric PET Study
- (2013) G. L. Poli et al. Cancer Immunology Research
- The Structural Basis of Antibody-Antigen Recognition
- (2013) Inbal Sela-Culang et al. Frontiers in Immunology
- B-cell-depleting Therapy in Systemic Lupus Erythematosus
- (2012) Manuel Ramos-Casals et al. AMERICAN JOURNAL OF MEDICINE
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab
- (2012) Nicholas Papadopoulos et al. ANGIOGENESIS
- Phase IB study of the EpCAM antibody adecatumumab combined with docetaxel in patients with EpCAM-positive relapsed or refractory advanced-stage breast cancer
- (2012) M. Schmidt et al. ANNALS OF ONCOLOGY
- Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease
- (2012) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Development of Anti-Infectives Using Phage Display: Biological Agents against Bacteria, Viruses, and Parasites
- (2012) Johnny X. Huang et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Selection and characterization of cell binding and internalizing phage antibodies
- (2012) Yu Zhou et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Engineering antibodies by yeast display
- (2012) Eric T. Boder et al. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
- Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
- (2012) Timothy S. Fisher et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Targeting the EGFR signaling pathway in cancer therapy
- (2012) Parthasarathy Seshacharyulu et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Antibody Phage Display Libraries: Contributions to Oncology
- (2012) Carmela Dantas-Barbosa et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer
- (2012) Kenneth J. Pienta et al. INVESTIGATIONAL NEW DRUGS
- Phase I Trial and Pharmacokinetic Study of Lexatumumab in Pediatric Patients With Solid Tumors
- (2012) Melinda S. Merchant et al. JOURNAL OF CLINICAL ONCOLOGY
- A Systematic Comparison of Free and Bound Antibodies Reveals Binding-Related Conformational Changes
- (2012) I. Sela-Culang et al. JOURNAL OF IMMUNOLOGY
- The Emerging Role of IL-17 in the Pathogenesis of Psoriasis: Preclinical and Clinical Findings
- (2012) David A. Martin et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies
- (2012) P. A. Erba et al. JOURNAL OF NUCLEAR MEDICINE
- Blocking Agent Optimization for Nonspecific Binding on Phage Based Magnetoelastic Biosensors
- (2012) Wen Shen et al. JOURNAL OF THE ELECTROCHEMICAL SOCIETY
- Antibodies for biodefense
- (2012) Jeffrey W. Froude et al. mAbs
- A strategy for risk mitigation of antibodies with fast clearance
- (2012) Isidro Hötzel et al. mAbs
- Solubility evaluation of murine hybridoma antibodies
- (2012) Stacey Spencer et al. mAbs
- Protein selection using yeast surface display
- (2012) Nimish Gera et al. METHODS
- Generating conformation-specific synthetic antibodies to trap proteins in selected functional states
- (2012) Marcin Paduch et al. METHODS
- The discovery and development of belimumab: the anti-BLyS–lupus connection
- (2012) William Stohl et al. NATURE BIOTECHNOLOGY
- The use of phage display to generate conformation-sensor recombinant antibodies
- (2012) Aftabul Haque et al. Nature Protocols
- Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors
- (2012) A. Gurney et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Engineering Aggregation-Resistant Antibodies
- (2012) Joseph M. Perchiacca et al. Annual Review of Chemical and Biomolecular Engineering
- Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor- , in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study
- (2011) G. R. Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs
- (2011) H. Ulrichts et al. BLOOD
- Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis
- (2011) B.E. Strober et al. BRITISH JOURNAL OF DERMATOLOGY
- Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma
- (2011) RD May et al. BRITISH JOURNAL OF PHARMACOLOGY
- Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox
- (2011) R. J. Kreitman et al. CLINICAL CANCER RESEARCH
- Interleukin-23: as a drug target for autoimmune inflammatory diseases
- (2011) Chunlei Tang et al. IMMUNOLOGY
- Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
- (2011) Geertje M. Bartelds JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Comparison of the efficiency of antibody selection from semi-synthetic scFv and non-immune Fab phage display libraries against protein targets for rapid development of diagnostic immunoassays
- (2011) Conrad E.Z. Chan et al. JOURNAL OF IMMUNOLOGICAL METHODS
- HuCAL PLATINUM, a Synthetic Fab Library Optimized for Sequence Diversity and Superior Performance in Mammalian Expression Systems
- (2011) Josef Prassler et al. JOURNAL OF MOLECULAR BIOLOGY
- Phage Display for the Generation of Antibodies for Proteome Research, Diagnostics and Therapy
- (2011) Thomas Schirrmann et al. MOLECULES
- Selection of antibodies against a single rare cell present in a heterogeneous population using phage display
- (2011) Morten Dræby Sørensen et al. Nature Protocols
- Human TH17 Cells Are Long-Lived Effector Memory Cells
- (2011) I. Kryczek et al. Science Translational Medicine
- Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis
- (2011) Lihi Eder et al. ARTHRITIS CARE & RESEARCH
- Two-Step in Vitro Antibody Affinity Maturation Enables Estradiol-17β Assays with More than 10-Fold Higher Sensitivity
- (2010) Norihiro Kobayashi et al. ANALYTICAL CHEMISTRY
- Phage display: Concept, innovations, applications and future
- (2010) Jyoti Pande et al. BIOTECHNOLOGY ADVANCES
- A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma
- (2010) A Younes et al. BRITISH JOURNAL OF CANCER
- Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
- (2010) T Trarbach et al. BRITISH JOURNAL OF CANCER
- Human anti-mouse antibody response to the injection of murine monoclonal antibodies against IL-6
- (2010) E. LEGOUFFE et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers
- (2010) N. R. Smith et al. CLINICAL CANCER RESEARCH
- A Phase I Pharmacologic Study of Necitumumab (IMC-11F8), a Fully Human IgG1 Monoclonal Antibody Directed Against EGFR in Patients with Advanced Solid Malignancies
- (2010) B. Kuenen et al. CLINICAL CANCER RESEARCH
- A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
- (2010) D. R. Camidge et al. CLINICAL CANCER RESEARCH
- The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma
- (2010) Manfred Johannsen et al. EUROPEAN JOURNAL OF CANCER
- Microselection - affinity selecting antibodies against a single rare cell in a heterogeneous population
- (2010) Morten Draeby Sørensen et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- A method for rapid, ligation-independent reformatting of recombinant monoclonal antibodies
- (2010) Martina L. Jones et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Application of a High-Throughput Screening Procedure with PEG-Induced Precipitation to Compare Relative Protein Solubility During Formulation Development with IgG1 Monoclonal Antibodies
- (2010) Todd J. Gibson et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- Prediction of Aggregation Prone Regions of Therapeutic Proteins
- (2010) Naresh Chennamsetty et al. JOURNAL OF PHYSICAL CHEMISTRY B
- Raxibacumab
- (2010) Sohini Mazumdar mAbs
- Development of a novel mammalian cell surface antibody display platform
- (2010) Chen Zhou et al. mAbs
- A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing–remitting or secondary progressive multiple sclerosis
- (2010) Timothy L Vollmer et al. Multiple Sclerosis Journal
- Ranibizumab for Macular Edema following Central Retinal Vein Occlusion
- (2010) David M. Brown et al. OPHTHALMOLOGY
- Phase II Study of the Human Anti-Epithelial Cell Adhesion Molecule Antibody Adecatumumab in Prostate Cancer Patients with Increasing Serum Levels of Prostate-Specific Antigen after Radical Prostatectomy
- (2010) Norbert Marschner et al. UROLOGIA INTERNATIONALIS
- An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer
- (2009) M. Schmidt et al. ANNALS OF ONCOLOGY
- Effect of long-term belimumab treatment on b cells in systemic lupus erythematosus: Extension of a phase II, double-blind, placebo-controlled, dose-ranging study
- (2009) Annett M. Jacobi et al. ARTHRITIS AND RHEUMATISM
- Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis
- (2009) Monica Else et al. BRITISH JOURNAL OF HAEMATOLOGY
- CAT-8015: A Second-Generation Pseudomonas Exotoxin A-Based Immunotherapy Targeting CD22-Expressing Hematologic Malignancies
- (2009) R. F. Alderson et al. CLINICAL CANCER RESEARCH
- Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor
- (2009) Zehra Kaymakcalan et al. CLINICAL IMMUNOLOGY
- The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus
- (2009) Michael P. Cancro et al. JOURNAL OF CLINICAL INVESTIGATION
- Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis
- (2009) L. van der Fits et al. JOURNAL OF IMMUNOLOGY
- AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells
- (2009) P. J. Beltran et al. MOLECULAR CANCER THERAPEUTICS
- Raxibacumab for the Treatment of Inhalational Anthrax
- (2009) Thi-Sau Migone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design of therapeutic proteins with enhanced stability
- (2009) N. Chennamsetty et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor-PI3K Axis
- (2009) B. Schoeberl et al. Science Signaling
- Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis
- (2008) Alexa B. Kimball ARCHIVES OF DERMATOLOGY
- Epidermal growth factor receptor immunohistochemistry
- (2008) Fred R. Hirsch et al. CANCER
- Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5
- (2008) C Adams et al. CELL DEATH AND DIFFERENTIATION
- Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy
- (2008) J. Marlind et al. CLINICAL CANCER RESEARCH
- Interaction of antibodies with ErbB receptor extracellular regions
- (2008) Karl R. Schmitz et al. EXPERIMENTAL CELL RESEARCH
- A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculaturein vivo
- (2008) Alessandra Villa et al. INTERNATIONAL JOURNAL OF CANCER
- Human Anti-gold Antibodies
- (2008) Hideki Watanabe et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Exceptionally Potent Cross‐Reactive Neutralization of Nipah and Hendra Viruses by a Human Monoclonal Antibody
- (2008) Zhongyu Zhu et al. JOURNAL OF INFECTIOUS DISEASES
- An Entirely Cell-Based System to Generate Single-Chain Antibodies against Cell Surface Receptors
- (2008) Barbara D. Lipes et al. JOURNAL OF MOLECULAR BIOLOGY
- The Human Combinatorial Antibody Library HuCAL GOLD Combines Diversification of All Six CDRs According to the Natural Immune System with a Novel Display Method for Efficient Selection of High-Affinity Antibodies
- (2008) Christine Rothe et al. JOURNAL OF MOLECULAR BIOLOGY
- Measuring and Increasing Protein Solubility
- (2008) Saul R. Trevino et al. JOURNAL OF PHARMACEUTICAL SCIENCES
- In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification
- (2008) Stefan Steidl et al. MOLECULAR IMMUNOLOGY
- Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: Functional and structural correlates
- (2008) Emanuela Pappalardo et al. MOLECULAR IMMUNOLOGY
- Directed evolution of a G protein-coupled receptor for expression, stability, and binding selectivity
- (2008) C. A. Sarkar et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Isolation of human monoclonal antibodies by mammalian cell display
- (2008) R. R. Beerli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Modelling the human immune response: performance of a 1011 human antibody repertoire against a broad panel of therapeutically relevant antigens
- (2008) C. Lloyd et al. PROTEIN ENGINEERING DESIGN & SELECTION
- A step-wise approach significantly enhances protein yield of a rationally-designed agonist antibody fragment in E. coli
- (2008) Bing Lin et al. PROTEIN EXPRESSION AND PURIFICATION
- Structural Basis for EGF Receptor Inhibition by the Therapeutic Antibody IMC-11F8
- (2008) Shiqing Li et al. STRUCTURE
- Selection of anti-cancer antibodies from combinatorial libraries by whole-cell panning and stringent subtraction with human blood cells
- (2007) Amara C. Siva et al. JOURNAL OF IMMUNOLOGICAL METHODS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation